TABLE 1.
Clinical characteristics and outcomes of the overall and propensity-score-matched adults in varied age groups*.
| Clinical variable | Overall patients |
Matched patients |
||||||
| Patient number (%) |
P value | Patient number (%) |
P value | |||||
| Middle-aged n = 968 | Old n = 683 | Very old n = 1265 | Middle-aged n = 582 | Old n = 582 | Very old n = 582 | |||
| Gender, male | 534 (55.2) | 309 (45.2) | 644 (50.9) | < 0.001 | 299 (51.4) | 260 (44.7) | 287 (49.3) | 0.06 |
| Nursing-home residence | 27 (2.8) | 31 (4.5) | 115 (9.1) | < 0.001 | 16 (2.7) | 22 (3.8) | 20 (3.4) | 0.61 |
| Fatal comorbidity (McCabe and Jackson classification) | 285 (29.4) | 195 (28.6) | 264 (20.9) | < 0.001 | 161 (27.7) | 163 (28.0) | 141 (24.2) | 0.27 |
| Major comorbidity | ||||||||
| Cardiovascular disease | 367 (37.9) | 406 (59.4) | 907 (71.7) | < 0.001 | 219 (37.6) | 347 (59.6) | 402 (69.1) | < 0.001 |
| Diabetes mellitus | 365 (37.7) | 320 (46.9) | 483 (38.2) | < 0.001 | 230 (39.5) | 263 (45.2) | 231 (39.7) | 0.08 |
| Hemato-oncology | 308 (31.8) | 239 (35.0) | 351 (27.7) | 0.003 | 196 (33.7) | 196 (33.7) | 195 (33.5) | 0.98 |
| Chronic kidney disease | 144 (14.9) | 131 (19.2) | 276 (21.8) | < 0.001 | 94 (16.2) | 115 (19.8) | 121 (20.8) | 0.11 |
| Liver cirrhosis | 170 (17.6) | 95 (13.9) | 100 (7.9) | < 0.001 | 65 (11.2) | 65 (11.2) | 64 (11.0) | 0.99 |
| Neurological disease | 87 (9.0) | 140 (20.5) | 497 (39.3) | < 0.001 | 60 (10.3) | 80 (13.7) | 77 (13.2) | 0.16 |
| Major source of bacteremia | ||||||||
| Urinary tract | 291 (30.1) | 240 (35.1) | 431 (34.1) | 0.05 | 205 (35.2) | 205 (35.2) | 200 (34.4) | 0.94 |
| Intra-abdominal | 130 (13.4) | 78 (11.4) | 133 (10.5) | 0.10 | 65 (11.2) | 68 (11.7) | 83 (14.3) | 0.23 |
| Pneumonia | 115 (11.9) | 88 (12.9) | 244 (19.3) | < 0.001 | 74 (12.7) | 73 (12.5) | 77 (13.2) | 0.94 |
| Skin and soft-tissue | 111 (11.5) | 52 (7.6) | 108 (8.5) | 0.01 | 61 (10.5) | 47 (8.1) | 51 (8.8) | 0.34 |
| Primary bacteremia | 80 (8.3) | 56 (8.2) | 72 (5.7) | 0.03 | 43 (7.4) | 48 (8.2) | 44 (7.6) | 0.85 |
| Biliary tract | 59 (6.1) | 63 (9.2) | 140 (11.1) | < 0.001 | 46 (7.9) | 52 (8.9) | 55 (9.5) | 0.64 |
| Liver abscess | 43 (4.4) | 24 (3.5) | 31 (2.5) | 0.03 | 16 (2.7) | 16 (2.7) | 17 (2.9) | 0.98 |
| Polymicrobial bacteremia | 74 (7.6) | 64 (9.4) | 151 (11.9) | 0.003 | 51 (8.8) | 51 (8.8) | 50 (8.6) | 0.99 |
| Inadequate source control during antibiotic therapy | 34 (3.5) | 20 (2.9) | 39 (3.1) | 0.77 | 12 (2.1) | 13 (2.2) | 14 (2.4) | 0.92 |
| Pitt bacteremia score ≥4 at onset | 168 (17.4) | 144 (21.1) | 297 (23.5) | 0.005 | 97 (16.7) | 111 (19.1) | 109 (18.7) | 0.52 |
| Duration, median (interquartile range) | ||||||||
| Delayed AAT, hour | 2 (1–7) | 2 (1–7) | 2 (1–10) | 0.82 | 2 (1–8) | 2 (1–8) | 2 (1–6) | 0.88 |
| IV antimicrobial therapy, day | 8 (5–15) | 5 (5–15) | 8.5 (5–15) | 0.11 | 8 (4–14) | 5 (8–15) | 8 (5–15) | 0.56 |
| Length of hospitalization, day | 10 (6–17) | 10 (6–18) | 10 (6–17) | 0.13 | 10 (5–18) | 10 (6–18) | 10 (6–17) | 0.87 |
| Crude mortality rate | ||||||||
| 15-day | 111 (11.5) | 75 (11.0) | 163 (12.9) | 0.39 | 72 (12.4) | 59 (10.1) | 70 (12.0) | 0.44 |
| 30-day | 138 (14.3) | 104 (15.2) | 207 (16.4) | 0.39 | 87 (14.9) | 82 (14.1) | 87 (14.9) | 0.89 |
AAT, appropriate antimicrobial therapy; IV, intravenous. *Data are expressed as numbers (%), unless indicated specifically. Boldface indicates statistical significance (P < 0.05) between groups in the univariable analysis.